Davabazaar in India Vision and Objective
Davabazaar in India website is a Pharma Trade Portal which caters to end patients and their relatives, chemist and medical stores, pharmacist and other pharma workers, doctors and nursing homes, hospitals and medical institutions, pharmaceutical manufactures and allied service providers, trade and manufactures associations.
For patients and relatives we have Ask-the-Doctor medical forums, health blogs, chats and patient health communities.
Drug Index Software
Very soon the drug index software will be available for download. This software and all further upgrades are available free of cost to chemist and medical doctors. Please register and get yourself verified. Pharmaceutical companies who wish to add their information should also register and get verified.
Pharma Overview
Submitted by Correspondent on Wed, 08/12/2009 - 00:24Pharmaceutical OverviewLast Updated: April 2009
Sector structure/Market size
The Indian pharmaceutical industry is driving product development and breaking new grounds in medicine research worldwide.
The Indian domestic pharmaceutical market is estimated to be US$ 10.76 billion in 2008 and is expected to grow at a high compound annual growth rate (CAGR) of 9.9 per cent till 2010 and thereafter at a CAGR of 9.5 per cent till 2015.
Community Rallies for Farmington Relay For Life - Patch.com
Submitted by Correspondent on Sun, 05/20/2012 - 17:00Jamie Oliver urges MPs to end academy junk food exemption - The Guardian
Submitted by Correspondent on Sun, 05/20/2012 - 04:36Georgia woman with flesh-eating disease in "critical" condition - Reuters
Submitted by Correspondent on Sun, 05/20/2012 - 01:51Most FDA Reviewers Not Told to Meet PDUFA Review Goals, GAO Finds
Submitted by Correspondent on Sat, 05/19/2012 - 02:30Meeting specific review goals for drugs and biologics is generally not a criterion in FDA reviewers’ performance plans, according to a Government Accountability Office (GAO) report requested by Congress.
Psychiatry Giant Sorry for Backing Gay 'Cure' - New York Times
Submitted by Correspondent on Sat, 05/19/2012 - 02:04FDA Warns Cold Sore Drugmaker as Review of OTC Skin Protectants Continues
Submitted by Correspondent on Sat, 05/19/2012 - 02:00The FDA has warned Quadex Pharmaceuticals that its cold sore treatment Viroxyn Professional was never approved as a new drug and does not conform to the formulation and labeling requirements for an OTC cold sore drug.
J&J Unit Tweaks Packaging Line After Imodium Recall
Submitted by Correspondent on Sat, 05/19/2012 - 01:00Johnson & Johnson (J&J) subsidiary McNeil Consumer Healthcare is modifying some of its packaging equipment after blister unit tears led to a recall of one lot, 53,892 packages, of diarrhea drug Imodium from wholesalers.
Actavis Launches First Generics of GSK Parkinson’s Drug Requip XL
Submitted by Correspondent on Sat, 05/19/2012 - 01:00Actavis is launching generic versions of GlaxoSmithKline’s (GSK) Parkinson’s disease drug Requip XL and believes they are the first in the U.S.
Baby Boomers Beware: Do you have this potential life threatening illness (aka ... - The Virginian-Pilot
Submitted by Correspondent on Sat, 05/19/2012 - 00:13FDA approves 7 companies to sell generic Plavix - CBS News
Submitted by Correspondent on Fri, 05/18/2012 - 23:46Why do men like meat? Answer may be obvious - Chicago Sun-Times
Submitted by Correspondent on Fri, 05/18/2012 - 23:23
Daily Mail
Why do men like meat? Answer may be obvious
Chicago Sun-Times
Weight management 'benefits' for mother and baby - BBC News
Submitted by Correspondent on Fri, 05/18/2012 - 20:34Nighttime fasting may foster weight loss - Los Angeles Times
Submitted by Correspondent on Fri, 05/18/2012 - 17:32
Los Angeles Times
Nighttime fasting may foster weight loss
Los Angeles Times
French approach to autism becomes talking point - gulfnews.com
Submitted by Correspondent on Fri, 05/18/2012 - 13:32US FDA Ahead Of Canada, Europe In Drug-Approval Race
Submitted by Correspondent on Fri, 05/18/2012 - 12:30The U.S. Food and Drug Administration (FDA) generally approves drug therapies faster and earlier than its counterparts in Canada and Europe, according to a new study by Yale School of Medicine researchers. The study counters perceptions that the drug approval process in the United States is especially slow. Led by second-year medical student Nicholas Downing and senior author Joseph S. Ross, M...
New mom diagnosed with flesh-eating bacteria days after giving birth - msnbc.com
Submitted by Correspondent on Fri, 05/18/2012 - 07:55Osiris shares climb on stem-cell therapy approval - BusinessWeek
Submitted by Correspondent on Fri, 05/18/2012 - 07:18Why this judge is a stoner - New York Daily News
Submitted by Correspondent on Fri, 05/18/2012 - 06:42Sex, age may affect athletes' concussion recovery - Reuters
Submitted by Correspondent on Fri, 05/18/2012 - 06:10Senate Leader Works to Move User Fees Forward, White House Backs Bill
Submitted by Correspondent on Fri, 05/18/2012 - 03:00The White House has thrown its support behind the latest Senate FDA user fee bill, S. 3187, as the chamber starts the first procedural steps to move it to the floor for a vote next week.
Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response
Submitted by Correspondent on Fri, 05/18/2012 - 02:30Amgen (NASDAQ:AMGN) announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.
Merck total revenues increase 3.2% to € 2.6 billion
Submitted by Correspondent on Fri, 05/18/2012 - 02:30The Merck Group's first-quarter 2012 total revenues rose 3.2% to € 2,645 million compared to € 2,564 million in the first quarter of 2011. Sales for the Group increased 3.5% to € 2,564 million in first quarter compared to € 2,478 million in the year-ago quarter.
Novartis Sees Positive Phase III Data for COPD Candidate
Submitted by Correspondent on Fri, 05/18/2012 - 02:30Novartis’ chronic obstructive pulmonary disease (COPD) candidate bested placebo in improving lung function, symptom relief and quality of life in a Phase III trial, setting it up for a 2014 U.S. filing.
Drugmakers Get More Tips on Dose Selection, In Vitro Methods for Biotech Drugs in ICH Guidance Addendum
Submitted by Correspondent on Fri, 05/18/2012 - 01:30Drugmakers will see more explanation of the proper nonclinical steps to support safety of clinical trials and marketing applications for biotech drugs in an International Conference on Harmonisation (ICH) guidance addendum, just issued by the FDA.